Structure-guided optimization of HIV integrase strand transfer inhibitors
More about Open Access at the CrickAuthors list
Xue Zhi Zhao Steven J Smith Daniel P Maskell Mathieu Métifiot Val Pye Katherine Fesen Christophe Marchand Yves Pommier Peter Cherepanov Stephen H Hughes Terrence R BurkeAbstract
Integrase mutations can reduce the effectiveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTIs), raltegravir (RAL) and elvitegravir (EVG). The second-generation agent, dolutegravir (DTG), has enjoyed considerable clinical success; however, resistance-causing mutations that diminish the efficacy of DTG have appeared. Our current findings support and extend the substrate envelope concept that broadly effective INSTIs can be designed by filling the envelope defined by the DNA substrates. Previously, we explored 1-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides as an INSTI scaffold, making a limited set of derivatives, and concluded that broadly effective INSTIs can be developed using this scaffold. Herein, we report an extended investigation of 6-substituents as well the first examples of 7-substituted analogues of this scaffold. While 7-substituents are not well-tolerated, we have identified novel substituents at the 6-position that are highly effective, with the best compound (6p) retaining better efficacy against a broad panel of known INSTI resistant mutants than any analogues we have previously described.
Journal details
Journal Journal of Medicinal Chemistry
Volume 60
Issue number 17
Pages 7315-7332
Available online
Publication date
Full text links
Publisher website (DOI) 10.1021/acs.jmedchem.7b00596
Figshare View on figshare
Europe PubMed Central 28737946
Pubmed 28737946
Keywords
Related topics
Type of publication